- Home
- CTSO vs ICCM Comparison
CTSO vs ICCM Comparison
Compare CTSO & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- ICCM
- Stock Information
- Founded
- CTSO 1997
- ICCM 2006
- Country
- CTSO United States
- ICCM Israel
- Employees
- CTSO N/A
- ICCM N/A
- Industry
- CTSO Medical/Dental Instruments
- ICCM
- Sector
- CTSO Health Care
- ICCM
- Exchange
- CTSO Nasdaq
- ICCM Nasdaq
- Market Cap
- CTSO 52.6M
- ICCM 59.9M
- IPO Year
- CTSO N/A
- ICCM N/A
- Fundamental
- Price
- CTSO $1.03
- ICCM $1.07
- Analyst Decision
- CTSO Buy
- ICCM Strong Buy
- Analyst Count
- CTSO 2
- ICCM 1
- Target Price
- CTSO $5.50
- ICCM $2.50
- AVG Volume (30 Days)
- CTSO 134.9K
- ICCM 321.2K
- Earning Date
- CTSO 08-12-2025
- ICCM 08-19-2025
- Dividend Yield
- CTSO N/A
- ICCM N/A
- EPS Growth
- CTSO N/A
- ICCM N/A
- EPS
- CTSO N/A
- ICCM N/A
- Revenue
- CTSO $35,332,238.00
- ICCM $3,273,000.00
- Revenue This Year
- CTSO $18.34
- ICCM $83.41
- Revenue Next Year
- CTSO $19.82
- ICCM $185.02
- P/E Ratio
- CTSO N/A
- ICCM N/A
- Revenue Growth
- CTSO 15.37
- ICCM 0.34
- 52 Week Low
- CTSO $0.71
- ICCM $0.48
- 52 Week High
- CTSO $1.61
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- CTSO 49.00
- ICCM 56.78
- Support Level
- CTSO $0.93
- ICCM $0.96
- Resistance Level
- CTSO $1.39
- ICCM $1.03
- Average True Range (ATR)
- CTSO 0.13
- ICCM 0.07
- MACD
- CTSO -0.02
- ICCM 0.01
- Stochastic Oscillator
- CTSO 34.92
- ICCM 87.81
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.